Chronic Obstructive Pulmonary Disease, Emphysema
Conditions
Brief summary
The goal of this pliot study al is to preliminarily evaluate the effectiveness and safety of transbronchial lung volume reduction surgery using the self-devloped endobronchial valves for chronic obstructive pulmonary disease patients with emphysema phenotype . The main questions it aims to answer are: Does self-devloped endobronchial valves improve the lung function、exercise capacity and symptons of participants? What surgery-related adverse events do participants have after transbronchial lung volume reduction surgery using the self-devloped endobronchial valves? Participants will: undergo transbronchial lung volume reduction surgery using the self-devloped endobronchial valves. receive follow-up before surgery (baseline) and 3 days, 4 weeks, 12weeks after surgery.
Interventions
PROCEDUREbronchoscopic lung volume reduction surgery using endobronchial valve
The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
Sponsors
China-Japan Friendship Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Patients with chronic obstructive pulmonary disease based on GOLD diagnostic criteria; * 2\. Age range from 40 to 85 years old (including 40 and 85 years old); * 3\. BMI ≤ 35kg/m2; * 4\. 15% ≤ FEV1% pred ≤ 45%; * 5\. TLC\>100% pred, RV\>140% pred, and DLCO/red% ≥ 20%; * 6\. 100m ≤ 6WMD ≤ 500m after rehabilitation training; * 7\. Quit smoking for more than 4 months; * 8\. The evaluation result of pulmonary bypass ventilation function is negative; * 9\. Participants in this clinical trial requires the signing of an informed consent form by the individual or legal representative.
Exclusion criteria
* 1\. Being pregnant or breastfeeding; * 2\. PaCO2\>50mmHg and/or PaO2\<45mmHg; * 3\. Obvious bronchiectasis or other infectious lung diseases; * 4\. Hospitalization due to pulmonary infection or acute exacerbation of COPD within the past 12 months prior to baseline assessment twice or more times; * 5\. Coagulation dysfunction, platelet count\<60e+09/L; * 6\. Myocardial infarction or congestive heart failure within the past 24 weeks; * 7\. Previous lobectomy, LVRS or lung transplantation; * 8\. Anticoagulant therapy that cannot be stopped before surgery; * 9\. Uncontrolled pulmonary arterial hypertension (systolic pulmonary arterial pressure\>45mmHg) or lungs diagnosed within the past 12 weeks Arterial hypertension; * 10\. Left ventricular ejection fraction (LVEF) within the past 12 weeks is less than 45%; * 11\. Pulmonary nodules that require intervention; * 12\. Patients participating in other clinical trials; * 13\. Individuals with other contraindications to bronchial operations; * 14\. Other circumstances that the researcher deems unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change in FEV1 relative to baseline | 12 weeks after surgery | The patient will undergo lung function tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change in RV relative to baseline | 12 weeks after surgery | The patient will undergo lung function tests, and residual volume (RV) will be recorded. |
| Percentage change in TLC relative to baseline | 12 weeks after surgery | The patient will undergo lung function tests, and total lung capacity (TLC) will be recorded. |
| Percentage change in DLCO relative to baseline | 12 weeks after surgery | The patient will undergo lung function tests, and the diffusing capacity for carbon monoxide (DLCO) will be recorded. |
| Percentage of subjects with FEV1 improvement ≥ 12% after bronchodilators | 12 weeks after surgery | The patient will undergo lung function tests. |
| Percentage change in mMRC grade relative to baseline | 12 weeks after surgery | The patient will receive a modified Medical Research Council (mMRC) questionnaire. |
| Percentage change in 6MWD relative to baseline | 12 weeks after surgery | The patient will undergo 6-minute walk test, and 6-minute walk distance (6MWD) will be recored. |
| the incidence of surgical-related adverse events | 12 weeks after surgery | The surgical-related adverse events refers to pneumothorax, valve displacement or shedding, granuloma formation and other surgical-related adverse events. |
| Percentage change in SGRQ score relative to baseline | 12 weeks after surgery | The patient will receive a St.Georges respiratory questionnaire (SGRQ) questionnaire survey. |
Countries
China
Contacts
Primary ContactGang Hou, MD
Outcome results
None listed